Antihypertensive effects of mibefradil: A double-blind comparison with diltiazem CD

Clinical Cardiology

Volumn 20, Issue 6, 1997, Pages 562-568

  Masse, Barry M ^a,g   Chrysant, Steven G ^b   Jain, Adesh ^c   Weir, Matthew ^d   Weiss, Robert ^e   Kobrin, Isaac ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Oklahoma Cardiovascular and Hypertension Center   (United States)

^c Department of Behavioural Science   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e Androscoggin Cardiology Associates   (United States)

^f HOFFMANN LA ROCHE INC   (United States)

^g SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Calcium antagonist; Diltiazem; Hypertension; Mibefradil

Indexed keywords

DILTIAZEM; MIBEFRADIL;

ARTICLE; CALCIUM ANTAGONISM; CHEMICAL STRUCTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG WITHDRAWAL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; HYPOTENSION; RANDOMIZED CONTROLLED TRIAL;

EID: 0031004582     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960200610     Document Type: Article

References (19)

1. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol 1989;13:754-759
2. 2+ channels by Ro 40-5967. Circ Res 1994;75:144-148
3. 2+ inward currents by Ro 40-5967 and verapamil: Relation to negative inotropy. Eur J Pharmacol 1991;196:205-207
4. ++ channels. J Pharmacol Exp Ther 1994;271:1483-1488
5. 2+ signaling in the cardiovascular system. Am J Cardiol 1996;78(suppl 9A):2-6
6. Clozel JP, Osterrieder W, Kleinbloesem CH, Welker HA, Schäppi B, Tudor R, Hefti F, Schmitt R, Eggers H: Ro 40-5967: A new nondihydropyridine calcium antagonist. Cardiovasc Drug Rev 1991;9:4-17
7. Welker HA, Eggers H, Kleinbloesem CH, Erb K, Breithaupt K, Butzer R, Beltz GG: Ro 40-5967: Pharmacokinetics of a new calcium antagonist. Eur J Clin Pharmacol 1989;36(suppl):A304
8. Bernink PJLM, Prager G, Schelling A, Kobrin I: Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967). Hypertension 1996;27:426-432
9. Bakx ALM, van der Wall EE, Braun S, Emanuelsson H, Bruschke AVG, Kobrin I: Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study. Am Heart J 1995;130:748-757
10. Clozel JP, Banken L, Osterrieder W: Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: Comparison with verapamil. J Cardiovasc Pharmacol 1989;14:713-721
11. 3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drug Ther 1990;4:731-736
12. Véniant M, Clozel JP, Hess P, Wolfgang R: Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol 1991;17:277-284
13. Schmitt R, Kleinbloesem CH, Belz GG, Schroeter V, Feifel U, Pozenel H, Kirch W, Halabi A, Woittiez AJ, Welker HA, van Brummden P: Hemodynamic and humoral effect of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther 1992;52:314-323
14. Rousseau ME Hayoshida W, van Eyll C, Hess OM, Benedict CR, Ahn S, Chapelle F, Kobrin I, Pouleur H: Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocker, mibefradil, in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Card 1996;28(4):972-979
15. Whelton A, Eff J, Magner DJ: Sustained antihypertensive activity of diltiazem SR: Double-blind, placebo-controlled study with a 24-hour ambulatory blood pressure monitoring. J Clin Pharmacol 1992;32:808-815
16. Felicetta JV, Serfer HM, Cutler NR, Comstock TJ, Huber GL, Weir MR, Hafner K, Park GD: A dose-response trial of once-daily diltiazem. Am Heart J 1992;123(4Pt 1):1022-1026
17. Woehler TR, Eff J, Graney W, Heald D, Ziemniak J, Magner D: Multicenter evaluation of the efficacy and safety of sustained-release diltiazem hydrochloride for the treatment of hypertension. Clin Ther 1992;14:148-157
18. Massie B, MacCarthy EP, Ramanathan RB, Weiss RJ, Anderson M, Eidelson BA, Labreche DG, Tubau JF, Vlep D, Bands D: Diltiazem and propranolol in mild to moderate essential hypertension as monotherapy or with hydrochlorothiazide. Ann Intern Med 1987;107:150-157
19. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EJ, Henderson WG: Single-drug therapy for hypertension in men, A comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914-921